Economic costs of chemotherapy-induced febrile neutropenia among patients with non-Hodgkin’s lymphoma in European and Australian clinical practice

Abstract

BackgroundEconomic implications of chemotherapy-induced febrile neutropenia (FN) in European and Australian clinical practice are largely unknown.MethodsData were obtained from a European (97%) and Australian (3%) observational study of patients with non-Hodgkin’s lymphoma (NHL) receiving CHOP (±rituximab) chemotherapy. For each patient, each cycle of chemotherapy within the course, and each occurrence of FN within cycles, was identified. Patients developing FN in a given cycle (“FN patients”), starting with the first, were matched to those who did not develop FN in that cycle (“comparison patients”), irrespective of subsequent FN events. FN-related healthcare costs (£2010) were tallied for the initial FN event as well as follow-on care and FN events in subsequent cycles.ResultsMean total cost was £5776 (95%CI £4928-£6713) higher for FN patients (n = 295) versus comparison patients, comprising £4051 (£3633-£4485) for the initial event and a difference of £1725 (£978-£2498) in subsequent cycles. Among FN patients requiring inpatient care (76% of all FN patients), mean total cost was higher by £7259 (£6327-£8205), comprising £5281 (£4810-£5774) for the initial hospitalization and a difference of £1978 (£1262-£2801) in subsequent cycles.ConclusionsCost of chemotherapy-induced FN among NHL patients in European and Australian clinical practice is substantial; a sizable percentage is attributable to follow-on care and subsequent FN events.

Cost-effectiveness of prophylactic granulocyte colony-stimulating factor for febrile neutropenia in breast cancer patients receiving FEC-D

“…As the cost of G-CSF increases, the ICERs for these treatment strategies will increase as a result. The costs of hospitalization for FN follow a similar trend, with estimates from the US being higher [51,52] and those in the UK being less costly [53,54]. Varying the cost of hospitalization between these values has less of an impact, with ICERs for FEC 9 3 (SP) ?…”

Economic burden of chemotherapy-induced febrile neutropenia in patients with lymphoma: A systematic review

“…Among the studies that were conducted in the US, the estimated cost ranged from $16,054 to $34,756 (2013 US$) [11,12,21,24,25]. Among the studies conducted out of the US, the estimated cost ranged from $5819 to $13,823 (2013 US$) [10,16,22,23,26]. The highest range of cost estimate of FN was found to be in the US, followed by Singapore, Europe, Australia, Canada and Spain.…”

“…The majority of the studies employed a healthcare provider perspective [10,16,[21][22][23]. Four other studies [11,[24][25][26] used a societal perspective. Two studies [11,24] accounted for indirect costs, but used different databases to account for their indirect costs.…”

“…Two studies [11,24] accounted for indirect costs, but used different databases to account for their indirect costs. Six studies used a retrospective cohort design analysis [12,[21][22][23]25,26]. The source of cost data for most of the studies was from claims databases and hospital records.…”

“…The study population size varied from 46 patients to cohorts of 5990 cases. There was one study [26] focused specifically on the lymphoma patients as its study population, while other cost studies included lymphoma and various other types of cancer patients in their study populations.…”